Advertisement
UK markets close in 8 hours 10 minutes
  • FTSE 100

    8,076.08
    +31.27 (+0.39%)
     
  • FTSE 250

    19,802.52
    +2.80 (+0.01%)
     
  • AIM

    756.44
    +1.57 (+0.21%)
     
  • GBP/EUR

    1.1631
    +0.0004 (+0.03%)
     
  • GBP/USD

    1.2432
    -0.0020 (-0.16%)
     
  • Bitcoin GBP

    53,786.65
    +398.21 (+0.75%)
     
  • CMC Crypto 200

    1,417.73
    -6.37 (-0.45%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    83.47
    +0.11 (+0.13%)
     
  • GOLD FUTURES

    2,335.70
    -6.40 (-0.27%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,207.68
    +378.75 (+2.25%)
     
  • DAX

    18,182.72
    +45.07 (+0.25%)
     
  • CAC 40

    8,104.81
    -0.97 (-0.01%)
     

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

ProQR Therapeutics N.V.
ProQR Therapeutics N.V.

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) --

ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference (TIDES USA), May 7-10, 2023 in San Diego, CA, USA.

ProQR presentation

Presentation title: Unlocking the Potential of Innovative Editing Oligonucleotides (EONs) to Address Liver Originated Disorders
Presenter: Gerard Platenburg, Co-Founder and Chief Scientific Officer at ProQR
Presentation type: Oral presentation
Session: Oligonucleotide Discovery, Preclinical and Clinical
Date: May 9, 2023 at 9:30am PDT

ADVERTISEMENT

During this scientific presentation, data describing findings of structure-activity relationship (SAR) assessment will be presented, including:

  • Modification of the orphan base in the Editing enabling region (EER) confirms superiority of dZ base on editing efficiency of the EONs,

  • Neutral linkage modifications in the ADAR-binding region (ABR) have a positive impact on editing efficiency of the EONs,

  • Further EON improvements led to approx. 50% editing in liver of mice. New optimizations are being evaluated (not disclosed in the presentation).

About Axiomer®

ProQR is pioneering a next-generation RNA base editing technology called Axiomer®, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer® “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer® EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

Forward Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our Axiomer® technology and our participation at this conference. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; and general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.

Investor contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com

Media contact:
Robert Stanislaro
FTI Consulting
T: +1 212 850 5657
robert.stanislaro@fticonsulting.com